In a significant escalation of an ongoing commercial and regulatory dispute, pharmaceutical giant Novo Nordisk has filed a lawsuit against…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, the medical community has grappled with the persistent challenge of mood disorders, offering successive waves of antidepressants that,…
Read More
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
In a significant development for vaccine innovation and public health, the U.S. Food and Drug Administration (FDA) has reversed its…
Read More
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands Compared
Simplifying workflows and enhancing patient safety are paramount in modern healthcare, making the integration of automated dispensing cabinets (ADCs) a…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…
Read More
Sai Life Sciences plans to recruit 700+ professionals in FY27 as Indian CRDMO demand accelerates
Hyderabad-based Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has announced ambitious plans to hire more…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk’s latest investigational weight loss treatment, CagriSema, has failed to achieve its primary endpoint of demonstrating non-inferiority when compared…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, achieving the coveted position of…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read MoreYOU MAY HAVE MISSED
